Dyslipidemia: Contemporary Evaluation and Management eReport

Page Count:
25
DOI:
https://doi.org/10.37573/9781585284719
Online ISBN:
9781585284719
Print ISBN:
9781585284719
Restricted access
Buy Book in ASHP Store

This product is no longer being sold.

Page Count: 25

Like all ASHP eReports, this is a brief and straightforward presentation of what you need to know about dyslipidemia treatment, the new guidelines, and where you can turn for deeper understanding of the context. Dyslipidemia: Contemporary Evaluation and Management addresses pathophysiology, clinical presentation, diagnosis, and disease classification, general treatment principles, non-pharmacological treatments, pharmacotherapy, monitoring, clinical controversies, and future treatment, references, and web resources.

Front Matter
Preliminary Material
Introduction
Table 1-1: Cholesterol Concentrations
Table 1-2: Epidemiologic Data for Dyslipidemia
Figure 1-1: Approach to Management of Dyslipidemia
Table 1-3: Comparison of ATP-III Guidelines, ACC/AHA 2013 Guidelines, and NLA Recommendations
Pathophysiology
Clinical Presentation, Diagnosis, and Disease Classification
Table 1-4: Major Risk Factors for ASCVD
Table 1-5: Criteria for Classification of ASCVD
Table 1-6: National Lipid Association Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and Levels to Consider Drug Therapy
General Treatment Principles
Table 1-7: Components of Dietary Recommendations
American College of Cardiology/American Heart Association Guidelines
Table 1-8. Statin intensity
National Lipid Association Recommendations
Table 1-9. Risk Indicators (Other than Major ASCVD Risk Factors) that Might Be Considered for Risk Refinement
Table 1-10. Drugs that Can Lead to or Worsen Dyslipidemias
Pharmacotherapy
Statins
Cholesterol Absorption Inhibitors
Bile Acid Sequestrants
Fibric Acid Derivatives
Nicotinic Acid
Omega-3 Fatty Acids
Table 1-11. Relative LDL-Lowering Efficacy of Statin and Statin-Based Therapies
Monitoring
Table 1-12: Lipid Effects of Nonstatin Agents
Table 1-13: Clinical Conditions that Can Worsen Lipid Profiles
Clinical Questions and Controversies
What Impact Do Statins Have on Cognitive Function?
Do Statins Cause or Worsen Type 2 Diabetes?
Are Statins Safe to Use in Patients with Chronic Liver Disease?
What Drug-Drug Interactions Impact Statin Therapy?
Can Fibrates Be Safely Added to a Statin for the Management of Hypertriglyceridemia?
What Is the Best Way to Manage Suspected Statin-Induced Myalgia?
Should Co-enzyme Q10 Be Recommended for the Treatment and/or Prevention of Statin-Associated Muscle Aches?
Which Risk Calculator Is Best?
What Is the Best Strategy to Manage Residual Cardiovascular Risk?
What LDL-C Level Is Too Low?
Should All Patients with an Acute Coronary Event or at High CHD Risk Be Started on High-Dose Statin Therapy?
What Is the Role of CRP in Determining CHD Risk and LDL-C Goals?
Back Matter
Future Treatments
References

NOTE: The link below allows you to download the ePub file. If you want the PDF files, click on Table of Contents, browse the chapters by clicking on the drop-down symbol ^, select a chapter, and you will see the DOWNLOAD PDF orange button in the upper right. Most ePub files can be opened in eBook readers, like the B&N Nook and Kobo eReader. These files have to be converted to .Mobi format before they are usable on the Amazon Kindle device or app. For your computer, the easiest way to open an ePub file is to double-click on it and let your PC decide which default application should open the file. If no program opens it, then you probably do not have an application installed that can view ePub files. ePub files can also be opened on a computer with various free programs including Adobe Digital Editions. If you have access to this title you can download the ePub here:

    • Dyslipidemia: Contemporary Evaluation and Management eReport (EPUB 410 KB)
    • Dyslipidemia: Contemporary Evaluation and Management eReport (PDF 888 KB)

After much anticipation, new dyslipidemia guidelines have been published by the American College of Cardiology (ACC) and American Heart Association (AHA). The guidelines are a major shift from specific lipid goals to a focus on risk reduction. All pharmacists will need to be familiar with these guidelines in order to provide optimal patient care. 

Like all ASHP eReports, this is a brief and straightforward presentation of what you need to know about dyslipidemia treatment, the new guidelines, and where you can turn for deeper understanding of the context. Dyslipidemia: Contemporary Evaluation and Management addresses pathophysiology, clinical presentation, diagnosis, and disease classification, general treatment principles, non-pharmacological treatments, pharmacotherapy, monitoring, clinical controversies, and future treatment, references, and web resources.

Evan M. Sisson, PharmD, MSHA, BCACP, CDE, FAADE

Evan M. Sisson is Professor, Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy in Richmond, VA. His current practice sites include an inner-city free clinic where he manages drug therapy under a collaborative practice agreement with the medical director. Prior to joining the faculty at VCU, Dr. Sisson worked in the interdisciplinary diabetes and lipid clinics at the Richmond Veterans Affairs Medical Center. Dr. Sisson is a Certified Diabetes Educator and a past member of the Board of Directors for the American Association of Diabetes Educators. 

Sisson is a frequent author on the topics of drug therapy for dyslipidemia and diabetes. Two recent book chapters include Pharmacotherapy for Glucose Management and Pharmacotherapy: Dyslipidemia and Hypertension in Persons with Diabetes in the 3rd edition of AADE’s Art and Science of Diabetes Self-Management Education. Additionally, he authored the 5th edition of AADE’s Quick Guide to Medications.

 

McKenzie Calhoun, PharmD

McKenzie Calhoun is an Assistant Professor in the Bill Gatton College of Pharmacy's Department of Pharmacy Practice at East Tennessee State University (ETSU). Dr. Calhoun also holds an adjunct faculty appointment in the Department of Family Medicine at James H. Quillen College of Medicine. She maintains a clinical pharmacy practice with the ETSU Family Physicians of Kingsport. She is faculty advisor for the ETSU chapter of the APhA Academy of Student Pharmacists and a member of TPA, APhA, ACCP, STFM, Kappa Psi, and Phi Lambda Sigma. Calhoun earned her Doctor of Pharmacy degree at ETSU Gatton College of Pharmacy; she completed a PGY1 residency in pharmacy practice at Veterans Affairs Tennessee Valley HealthcareSystem in Nashville, TN, and a PGY2 residency in ambulatory care at ETSU Gatton College of Pharmacy.

Dr. Calhoun’s past awards included Outstanding Clinical Preceptor (2013-2014), Attending of the Year (2013-2014), Faculty of the Year (2014-2015), and Outstanding Clinical Preceptor (2014-2015).

 

Michael A. Crouch, PharmD, FASHP

Michael A. Crouch serves as the Fred E. McWhorter Dean and Professor at Samford University’s McWhorter School of Pharmacy. His education includes a Bachelor of Science in Pharmacy from the University of North Carolina followed by a first-year pharmacy residency at Wake Forest University Baptist Medical Center. Crouch also received a Doctor of Pharmacy from the Medical University of South Carolina where he completed a second-year residency focused on cardiology. Before joining Samford in 2014, he served on the faculty of Virginia Commonwealth University (Assistant then Associate Professor of Pharmacy and Medicine), South University (Chair and Professor), and East Tennessee State University (Associate Dean for Academic Affairs then Executive Associate Dean).

Dr. Crouch was the recipient of the Excellence in Teaching Award, 2001; Excellence in Teaching Award, 2000; and Teacher of the Year Award, 1998. Crouch has served as editor for two books: Cardiovascular Pharmacotherapy: A Point-of-Care Guide and Securing and Excelling in a Pharmacy Residency. He presently serves on the Birmingham Veterans Affairs Quality Scholars Advisory Committee, Albert Schweitzer of Alabama Advisory Council, Tuscaloosa Research and Education Advancement Board, and Paraguay Baptist Medical Center Foundation Board.